pharmaphorum
JULY 28, 2022
Benny discusses SparkRx, Limbix’s product, and how it works, addressing the current regulatory landscape, how digital therapeutics interact with talk therapy and traditional therapeutics, and why it’s important to build a bespoke product for teens.
pharmaphorum
MAY 9, 2022
SparkRx is designed to decrease depression in individuals aged 13 to 22 by providing a multi-week programme based on cognitive behavioural therapy (CBT) and behavioural activation protocols. “In In primary care, there are guidelines to screening for behavioural health concerns like depression annually.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
MARCH 3, 2022
DarioHealth has beefed up its sales and marketing channels as well as its range of digital health products thanks to a $30 million strategic alliance with drugmaker Sanofi. In February it also agreed a deal to acquire Physimax Technologies, which develops computer vision systems for musculoskeletal screening and injury assessments.
pharmaphorum
DECEMBER 16, 2022
Digital therapeutics company Cognoa, which focuses on paediatric behavioural health, announced the appointment of Dr Sharief Taraman as its new CEO. Reagents supplier The Native Antigen Company has hired a new business development manager, Richard White , and senior product manager, Pardeep Sharda. Digital therapeutics hires.
pharmaphorum
APRIL 23, 2021
The company has been pushing for more reimbursement of its three marketed DTx products in the US following a first FDA approval in 2017. Pear noted that the grant comes at a time when many communities are seeing increased demand for behavioural health and recovery services amid the ongoing coronavirus pandemic.
pharmaphorum
OCTOBER 2, 2020
Like its earlier digital therapies for alcohol misuse and depression , Modia’s earlier-than-expected rollout stems from legislation that has made it possible to secure reimbursement for certain digital products for psychiatric disorders during the COVID-19 pandemic.
pharmaphorum
APRIL 25, 2022
Aaron Gani, founder and CEO of BehaVR, and Krys Zaluski, director of business development, digital health at Sumitomo Dainippon Pharma, discuss their groundbreaking partnership to develop and commercialise digital therapeutics (DTx) products. . Gani started BehaVR in 2016 to create DTx for mental and behavioural health.
Expert insights. Personalized for you.
52 
Let's personalize your content